15 insiders reported 238 Form 4 transactions for CYTOKINETICS INC (CYTK) over the past 18 months (most recent 2026-07-07). Recent activity: Malik Fady Ibraham (EVP Research & Development) Buy 3,500 shares, Malik Fady Ibraham (EVP Research & Development) Sell 3,500 shares, Lee Sung (EVP, Chief Financial Officer) Buy 1,112 shares, Callos Andrew (EVP, Chief Commercial Officer) Buy 15,000 shares, Blum Robert I (President & CEO) Sell 7,500 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-07 | Malik Fady Ibraham | EVP Research & Development | Buy | 3,500 | $27,300 |
| 2026-07-07 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $303,170 |
| 2026-07-02 | Lee Sung | EVP, Chief Financial Officer | Buy | 1,112 | $53,943 |
| 2026-07-02 | Callos Andrew | EVP, Chief Commercial Officer | Buy | 15,000 | $348,900 |
| 2026-07-02 | Blum Robert I | President & CEO | Sell | 7,500 | $636,900 |
| 2026-07-02 | Lee Sung | EVP, Chief Financial Officer | Sell | 1,112 | $97,622 |
| 2026-07-02 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $1.3M |
| 2026-06-23 | Malik Fady Ibraham | EVP Research & Development | Buy | 3,500 | $27,300 |
| 2026-06-23 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $278,285 |
| 2026-06-09 | Malik Fady Ibraham | EVP Research & Development | Buy | 3,500 | $27,300 |
| 2026-06-09 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $237,930 |
| 2026-06-01 | Kaye Edward M. MD | Director | Sell | 2,933 | $223,172 |
| 2026-06-01 | PARSHALL B LYNNE | Director | Sell | 5,000 | $370,400 |
| 2026-06-01 | Callos Andrew | EVP, Chief Commercial Officer | Buy | 15,000 | $348,900 |
| 2026-06-01 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $1.1M |
| 2026-05-20 | Malik Fady Ibraham | EVP Research & Development | Buy | 3,500 | $27,300 |
| 2026-05-20 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $264,915 |
| 2026-05-14 | Blum Robert I | President & CEO | Sell | 7,500 | $584,400 |
| 2026-04-30 | Callos Andrew | EVP, Chief Commercial Officer | Buy | 15,000 | $348,900 |
| 2026-04-30 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $948,900 |
| 2026-04-21 | Malik Fady Ibraham | EVP Research & Development | Buy | 3,500 | $27,300 |
| 2026-04-21 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $229,915 |
| 2026-04-15 | Kaye Edward M. MD | Director | Buy | 191 | $12,486 |
| 2026-04-15 | HENDERSON JOHN T | Director | Buy | 325 | $21,245 |
| 2026-04-15 | WIERENGA WENDELL | Director | Buy | 95 | $6,210 |
Source: SEC Form 4 filings · as of 2026-07-07